Roche has a rare breast cancer setback
Giredestrant fails, but the group hopes for better luck in earlier therapy lines.
AACR 2022 – Novartis’s late Kras challenge to Amgen
Targeting Shp2 has disappointed, but Novartis shows that it might still make an impression in directly hitting Kras.
AACR 2022 – Affimed shows that 2021 was no fluke
An academic-sponsored trial gives Affimed’s NK cell engaging approach a huge endorsement.
Protagonist seeks an Ideal readout
A mid-stage hit with its ulcerative colitis project could see the company on course for blockbuster sales.
Despite slow progress, Boehringer keeps faith in oncology
The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.
